Nike is set to bring back a fan-favorite classic with a fresh twist this spring. The Air Force 1 Low “Linen,” a beloved ...

Nike has unveiled its latest silhouette, the Air Max Dn8, designed to elevate all-day wear through Dynamic Air technology. The sneaker introduces a first-time full-length Dynamic Air system, featuring ...

Nearly a year after debuting a new type of cushioning in the Air Max Dn, Nike is now doubling its use of Dynamic Air technology for its successor. The Nike Air Max Dn8 extends its use of Dynamic Air ...

A direct sequel to last year’s Air Max Dn, the Dn8 builds upon its predecessor’s foundational “Dynamic Air” technology, which employed a new four-tubed Nike Air unit in th ...

Another adds, "Love these shoes! They are very comfortable. The soles are thicker than the regular Air Max shoes and they ...

Nike launched the Air Max Plus series, and the sneaker range gained fame due to its specialized features in its year of introduction, 1998.

Nike Air Max Plus is potentially going green for St. Patrick's Day. While the official color names haven't been confirmed, ...

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and Vertex Pharmaceuticals (VRTX). But which of these two stocks presents investors with the ...

Vertex Pharmaceuticals (VRTX) closed at $428 in the latest trading session, marking a +0.03% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.61%.

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...

In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $402.00. The company’s ...